“We didn’t include women in clinical trials until 1993. We didn’t study women. We don’t have enough data on women. We owe women decades of scientific advancement, and now it’s time to deliver.”

The founder and managing partner of The Women’s Health Fund announced a new vehicle designed not just to invest in women’s health companies, but to systematically build a market that has been under-recognized, under-funded, and under-prioritized. “We didn’t include women in clinical trials until 1993. We didn’t study women. We don’t have enough data on women,” Federer told the audience. “We owe women decades of scientific advancement, and now it’s time to deliver.”

This is a story about what happens when life sciences leaders and experienced fund managers with a cumulative billions in AUM decide to come together to systematically change how women's health innovation is funded.

Deliberate Market Building Is Next Step to Close the Women’s Health Gap - headline from Citeline news published on October 14, 2025 by Lucie Ellis-Taitt

Conceptualized in partnership with industry leaders and fund managers, The Women’s Health Fund represents an innovative approach to sustainably build a market. By partnering with experienced life science managers with billions in AUM, this new vehicle intends to activate venture funds to allocate more capital into a space that has been historically under-recognized, under-funded and under-prioritized.